

September 9, 2020

Listing Department
BSE LIMITED

P J Towers, Dalal Street, Fort,
Mumbai – 400 001

Code: 532 321

Listing Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Code: CADILAHC

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated September 9, 2020 titled “Zydus Cadila receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

DHAVAL
NARENDRA
SONI

Digitally signed by DHAVAL
NARENDRA SONI
DN: cn=DHAVAL NARENDRA SONI, o=CADILA HEALTHCARE LIMITED, email=DHAVAL.NARENDRA.SONI@ZYDUSCADILA.COM

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Cadila receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets

Ahmedabad, September 09, 2020

Zydus Cadila has received tentative approval from the USFDA to market Empagliflozin and Linagliptin Tablets (US RLD: Glyxambi Tablets) in the strengths of 10 mg/5 mg and 25 mg/5 mg.

This medication contains a combination of Empagliflozin and Linagliptin. Empagliflozin and Linagliptin are oral diabetes medicines that help control blood sugar levels. The drug is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 299 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.
